Format

Send to

Choose Destination
ACS Chem Biol. 2014 Nov 21;9(11):2471-8. doi: 10.1021/cb500515r. Epub 2014 Sep 3.

Small-molecule inhibitors of SETD8 with cellular activity.

Author information

1
Molecular Pharmacology and Chemistry Program, ‡Tri-Institutional Training Program in Chemical Biology, and §HTS Core Facility, Memorial Sloan Kettering Cancer Center , New York, New York 10065, United States.

Abstract

SETD8/SET8/Pr-SET7/KMT5A is the sole protein lysine methyltransferase (PKMT) known to monomethylate lysine 20 of histone H4 in vivo. SETD8's methyltransferase activity has been implicated in many essential cellular processes including DNA replication, DNA damage response, transcription modulation, and cell cycle regulation. Developing SETD8 inhibitors with cellular activity is a key step toward elucidating the diverse roles of SETD8 via convenient pharmacological perturbation. From the hits of a prior high throughput screen (HTS), SPS8I1-3 (NSC663284, BVT948, and ryuvidine) were validated as potent SETD8 inhibitors. These compounds contain different structural motifs and inhibit SETD8 via distinct modes. More importantly, these compounds show cellular activity by suppressing the H4K20me1 mark of SETD8 and recapitulate characteristic S/G2/M-phase cell cycle defects as observed for RNAi-mediated SETD8 knockdown. The commonality of SPS8I1-3 against SETD8, together with their distinct structures and mechanisms for SETD8 inhibition, argues for the collective application of these compounds as SETD8 inhibitors.

PMID:
25137013
PMCID:
PMC4245162
DOI:
10.1021/cb500515r
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center